Mesoblast (MESO) Price & Analysis

Compare

900 Followers

MESO Stock Chart & Stats

$17.65

-$0.53(-2.96%)

At close: Jan 08 4:00 PM EST

$17.65

-$0.53(-2.96%)

Day’s Range― - ―

52-Week Range$9.61 - $22.00

Previous CloseN/A

Volume155.35K

Average Volume (3M)174.75K

Market Cap

$2.28B

Enterprise Value$1.35B

Total Cash (Recent Filing)$38.03M

Total Debt (Recent Filing)$126.11M

Price to Earnings (P/E)―

Beta1.37

Next Earnings

Feb 26, 2026

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding128,296,720

10 Day Avg. Volume162,139

30 Day Avg. Volume174,747

Financial Highlights & Ratios

PEG Ratio2.44

Price to Book (P/B)2.20

Price to Sales (P/S)76.48

P/FCF Ratio-25.95

Enterprise Value/Market Cap0.59

Enterprise Value/Revenue238.47

Enterprise Value/Gross Profit-59.92

Enterprise Value/Ebitda-27.36

Forecast

1Y Price Target

$29.50

Price Target Upside67.14% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.2

Revenue Forecast (FY)$93.38M

Bulls Say, Bears Say

Bulls Say

Market ExpansionExpansion plans for Ryoncil include targeting adult severe steroid-refractory acute graft versus host disease, potentially tripling the current market size.

Regulatory ProgressPositive feedback from the FDA on potential accelerated BLA filing for rexlemestrocel in chronic heart failure indicates promising regulatory progress.

Revenue GrowthRyoncil gross sales in steroid-refractory acute graft vs. host disease increased to $21.9M in the September quarter, up 66% from the June quarter.

Bears Say

Mesoblast News

Mesoblast upgraded to Buy at Jefferies as Ryoncil roll out continues

As previously reported, Jefferies analyst David Stanton upgraded Mesoblast (MESO) to Buy from Hold with a price target...

3d ago

MESO

Mesoblast upgraded to Buy from Hold at Jefferies

Jefferies upgraded Mesoblast (MESO) to Buy from Hold with a price target of A$3.30, up from A$3. Published...

3d ago

MESO

Mesoblast collaborating with BMT CTN on trial of Ryoncil in acute GvHD

Mesoblast (MESO) announced that, given the high rate of non-responsiveness to therapies in adults with severe acute graft...

8d ago

MESO

Mesoblast appoints James O’Brien as CFO

Mesoblast (MESO) announced that in connection with the company’s transition to a fully integrated commercial organization it has...

11d ago

ABBV

MESO

Mesoblast’s AGM Results: All Resolutions Passed on November 25, 2025

Mesoblast ( ($MESO) ) has provided an announcement. On November 25, 2025, Mesoblast Limited announced the results of...

2d ago

MESO

Mesoblast Achieves FDA Approval for Ryoncil®

An update from Mesoblast ( ($MESO) ) is now available. On November 25, 2025, Mesoblast Limited announced at...

3d ago

MESO

Mesoblast to Launch Pivotal Ryoncil® Trial for Severe aGvHD in Adults

Mesoblast ( ($MESO) ) has issued an announcement. On November 21, 2025, Mesoblast Limited announced a collaboration with...

4d ago

MESO

Mesoblast Announces Director’s Share Acquisition and New Equity Issuance

An update from Mesoblast ( ($MESO) ) is now available. On October 28, 2025, Mesoblast Limited announced a...

1M ago

MESO

Mesoblast’s Promising Study on Chronic Low Back Pain Treatment: A Market Game Changer?

Mesoblast (($MESO)) announced an update on their ongoing clinical study. Study Overview: Mesoblast is conducting a clinical study...

1M ago

MESO

Mesoblast Reports Strong Revenue Growth with Ryoncil® Adoption

Mesoblast ( ($MESO) ) just unveiled an update. On October 20, 2025, Mesoblast Limited reported a significant increase...

1M ago

MESO

Mesoblast reports Q2 Ryoncil revenue up 66% y/y

Mesoblast (MESO) “announced gross revenue of $21.9 million on Ryoncil (remestemcel-L-rknd) sales for the quarter ended September 30,...

2M ago

MESO

Mesoblast receives J-Code for Ryoncil from Medicare & Medicaid Services

Mesoblast (MESO) announced that a specific Healthcare Common Procedure Coding System J-Code assigned to Ryoncil by United States...

2M ago

MESO

Mesoblast’s U.S. Origin Designation Shields Products from Tariffs

Mesoblast ( ($MESO) ) has shared an announcement. On September 26, 2025, Mesoblast Limited announced that its allogeneic...

2M ago

MESO

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: CEA Industries Inc (BNC)...

2M ago

BNC

MBX

MESO FAQ

What was Mesoblast’s price range in the past 12 months?

Mesoblast lowest stock price was $9.61 and its highest was $22.00 in the past 12 months.

What is Mesoblast’s market cap?

Mesoblast’s market cap is $2.28B.

When is Mesoblast’s upcoming earnings report date?

Mesoblast’s upcoming earnings report date is Feb 26, 2026 which is in 90 days.

How were Mesoblast’s earnings last quarter?

Mesoblast released its earnings results on Aug 28, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.373 by -$0.057.

Is Mesoblast overvalued?

According to Wall Street analysts Mesoblast’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mesoblast pay dividends?

Mesoblast does not currently pay dividends.

What is Mesoblast’s EPS estimate?

Mesoblast’s EPS estimate is -0.11.

How many shares outstanding does Mesoblast have?

Mesoblast has 128,296,720 shares outstanding.

What happened to Mesoblast’s price movement after its last earnings report?

Mesoblast reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.373. Following the earnings report the stock price went down -13.292%.

Which hedge fund is a major shareholder of Mesoblast?

Currently, no hedge funds are holding shares in MESO

Mesoblast Stock Smart Score

Outperform

Fundamentals

Return on Equity

-18.96%

Trailing 12-Months

Asset Growth

17.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mesoblast

Mesoblast Limited (NASDAQ: MESO) is a global leader in developing innovative cellular medicines. The company focuses on regenerative medicine, specifically the use of adult stem cells to treat various diseases and conditions, including heart disease, chronic lower back pain, and inflammatory conditions. Mesoblast's proprietary technology platforms enable the development of products that leverage the unique properties of mesenchymal stem cells (MSCs) to promote healing and repair in damaged tissues.

Mesoblast (MESO) Earnings & Revenues

Historic Earnings Reports

MESO Company Deck

MESO Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call illustrated significant growth and successful product launch achievements, particularly with Ryoncil's market penetration and FDA approval. However, increased operational expenses and revaluation-related losses presented financial challenges. Overall, the company's positive strides in market access and regulatory feedback indicate strong potential for future growth.View all MESO earnings summaries

MESO Stock 12 Month Forecast

Average Price Target

$29.50

▲(67.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","36":"$36","14.25":"$14.25","21.5":"$21.5","28.75":"$28.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,14.25,21.5,28.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.66,18.07076923076923,19.481538461538463,20.892307692307693,22.303076923076922,23.713846153846156,25.124615384615385,26.535384615384615,27.946153846153848,29.356923076923078,30.767692307692307,32.17846153846154,33.58923076923077,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.66,17.647692307692306,18.635384615384616,19.623076923076923,20.61076923076923,21.59846153846154,22.586153846153845,23.573846153846155,24.56153846153846,25.549230769230768,26.536923076923078,27.524615384615384,28.512307692307694,{"y":29.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.66,17.224615384615383,17.78923076923077,18.353846153846153,18.91846153846154,19.483076923076922,20.04769230769231,20.61230769230769,21.176923076923078,21.74153846153846,22.306153846153848,22.87076923076923,23.435384615384613,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.14,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.94,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.38,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.12,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":15.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >